Murchinson Ltd. Nymox Pharmaceutical Corp Call Options Transaction History
Murchinson Ltd.
- $342 Million
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding NYMX
# of Institutions
6Shares Held
150KCall Options Held
0Put Options Held
0-
Df Dent & CO Inc Baltimore, MD75KShares$35,2500.0% of portfolio
-
First Citizens Financial Corp35.1KShares$16,4970.01% of portfolio
-
Gofen & Glossberg LLC25KShares$11,7500.0% of portfolio
-
Cubic Asset Management, LLC10KShares$4,7000.0% of portfolio
-
Bdo Wealth Advisors, LLC Jacksonville, FL4.7KShares$2,2090.0% of portfolio
About NYMOX PHARMACEUTICAL CORP
- Ticker NYMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 91,265,000
- Market Cap $42.9M
- Description
- Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperpl...